Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2014 2
2015 2
2016 1
2017 2
2018 4
2019 4
2020 6
2021 5
2022 3
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Results by year

Filters applied: . Clear all
Page 1
Cotargeting of BTK and MALT1 overcomes resistance to BTK inhibitors in mantle cell lymphoma.
Jiang VC, Liu Y, Lian J, Huang S, Jordan A, Cai Q, Lin R, Yan F, McIntosh J, Li Y, Che Y, Chen Z, Vargas J, Badillo M, Bigcal JN, Lee HH, Wang W, Yao Y, Nie L, Flowers CR, Wang M. Jiang VC, et al. Among authors: badillo m. J Clin Invest. 2023 Feb 1;133(3):e165694. doi: 10.1172/JCI165694. J Clin Invest. 2023. PMID: 36719376 Free PMC article.
Ibrutinib With Rituximab in First-Line Treatment of Older Patients With Mantle Cell Lymphoma.
Jain P, Zhao S, Lee HJ, Hill HA, Ok CY, Kanagal-Shamanna R, Hagemeister FB, Fowler N, Fayad L, Yao Y, Liu Y, Moghrabi OB, Navsaria L, Feng L, Nogueras Gonzalez GM, Xu G, Thirumurthi S, Santos D, Iliescu C, Tang G, Medeiros LJ, Vega F, Avellaneda M, Badillo M, Flowers CR, Wang L, Wang ML. Jain P, et al. Among authors: badillo m. J Clin Oncol. 2022 Jan 10;40(2):202-212. doi: 10.1200/JCO.21.01797. Epub 2021 Nov 19. J Clin Oncol. 2022. PMID: 34797699 Free PMC article. Clinical Trial.
The HSP90-MYC-CDK9 network drives therapeutic resistance in mantle cell lymphoma.
Yan F, Jiang V, Jordan A, Che Y, Liu Y, Cai Q, Xue Y, Li Y, McIntosh J, Chen Z, Vargas J, Nie L, Yao Y, Lee HH, Wang W, Bigcal JR, Badillo M, Meena J, Flowers C, Zhou J, Zhao Z, Simon LM, Wang M. Yan F, et al. Among authors: badillo m. Exp Hematol Oncol. 2024 Feb 7;13(1):14. doi: 10.1186/s40164-024-00484-9. Exp Hematol Oncol. 2024. PMID: 38326887 Free PMC article.
Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib.
Jain P, Kanagal-Shamanna R, Zhang S, Ahmed M, Ghorab A, Zhang L, Ok CY, Li S, Hagemeister F, Zeng D, Gong T, Chen W, Badillo M, Nomie K, Fayad L, Medeiros LJ, Neelapu S, Fowler N, Romaguera J, Champlin R, Wang L, Wang ML. Jain P, et al. Among authors: badillo m. Br J Haematol. 2018 Nov;183(4):578-587. doi: 10.1111/bjh.15567. Epub 2018 Sep 2. Br J Haematol. 2018. PMID: 30175400 Free article.
Ibrutinib-rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial.
Wang ML, Jain P, Zhao S, Lee HJ, Nastoupil L, Fayad L, Ok CY, Kanagal-Shamanna R, Hill HA, Yao Y, Hagemeister FB, Westin JR, Fowler N, Samaniego F, Steiner R, Nair R, Iyer SP, Navsaria L, Badillo M; Mantle Cell Research Group; Feng L, Xuelin H, Nogueras Gonzalez GM, Xu G, Wagner-Bartak N, Thirumurthi S, Santos D, Tang G, Lin P, Wang SA, Jorgensen J, Yin CC, Li S, Patel KP, Vega F, Medeiros LJ, Flowers CR, Wang L. Wang ML, et al. Among authors: badillo m. Lancet Oncol. 2022 Mar;23(3):406-415. doi: 10.1016/S1470-2045(21)00638-0. Epub 2022 Jan 21. Lancet Oncol. 2022. PMID: 35074072 Clinical Trial.
Outcomes of relapsed mantle cell lymphoma patients after discontinuing acalabrutinib.
Jain P, Kanagal-Shamanna R, Zhang S, Ok CY, Navsaria L, Nastoupil L, Lee HJ, Tang G, Yin CC, Badillo M, Nair R, Li S, Patel KM, Flowers C, Vega F, Wang L, Wang ML. Jain P, et al. Among authors: badillo m. Am J Hematol. 2021 May 1;96(5):E137-E140. doi: 10.1002/ajh.26109. Epub 2021 Feb 11. Am J Hematol. 2021. PMID: 33491779 Free article. No abstract available.
SARS-CoV-2 in eight municipalities of the Colombian tropics: high immunity, clinical and sociodemographic outcomes.
Garay E, Serrano-Coll H, Rivero R, Gastelbondo B, Faccini-Martínez Á, Berrocal J, Pérez A, Badillo M, Martínez-Bravo C, Botero Y, Arrieta G, Calderón A, Galeano K, López Y, Miranda J, Guzmán C, Contreras V, Arosemena A, Contreras H, Brango-Tarra E, Oviedo M, Mattar S. Garay E, et al. Among authors: badillo m. Trans R Soc Trop Med Hyg. 2022 Feb 1;116(2):139-147. doi: 10.1093/trstmh/trab094. Trans R Soc Trop Med Hyg. 2022. PMID: 34185868 Free PMC article.
Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma.
Zhang S, Jiang VC, Han G, Hao D, Lian J, Liu Y, Zhang R, McIntosh J, Wang R, Dang M, Dai E, Wang Y, Santos D, Badillo M, Leeming A, Chen Z, Hartig K, Bigcal J, Zhou J, Kanagal-Shamanna R, Ok CY, Lee H, Steiner RE, Zhang J, Song X, Nair R, Ahmed S, Rodriquez A, Thirumurthi S, Jain P, Wagner-Bartak N, Hill H, Nomie K, Flowers C, Futreal A, Wang L, Wang M. Zhang S, et al. Among authors: badillo m. Nat Commun. 2021 May 17;12(1):2877. doi: 10.1038/s41467-021-22872-z. Nat Commun. 2021. PMID: 34001881 Free PMC article.
27 results